Meridian Bioscience Receives FDA Clearance for New Premier C. difficile GDH Assay

Meridian Bioscience, Inc. VIVO today announced that it has received clearance from the U.S. Food and Drug Administration for a new Clostridium difficile immunoassay named Premier™ C. difficile GDH. This product expands the Company's existing portfolio of C. difficile tests and has been available in Europe and the rest of world since October of 2010. The assay detects a common antigen produced by toxigenic and non-toxigenic forms of C. difficile bacteria.